Cite
HARVARD Citation
Shapira-Frommer, R. et al. (n.d.). O83 Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. p. A2. [Online].